Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Glycopyranosyl lipid adjuvant (Primary) ; Pembrolizumab
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Immune Design
- 12 Mar 2018 According to an Immune Design media release, results from this trial were presented at the American Society of Hematology Annual Meeting (ASH 2017).
- 12 Mar 2018 Results published in an Immune Design media release.
- 16 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History